Cellectis SA
CLLS3.570USD
+0.070+2.00%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
258.20M시가총액
손실P/E TTM
자세한 내용은 Cellectis SA 회사
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Cellectis SA 정보
종목 코드 CLLS
회사 이름Cellectis SA
상장일Feb 06, 2007
CEOSourdive (David J.D)
직원 수224
유형Depository Receipt
회계 연도 종료Feb 06
주소8, rue de la Croix Jarry
도시PARIS
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가France
우편 번호75013
전화33181691600
웹사이트https://www.cellectis.com/
종목 코드 CLLS
상장일Feb 06, 2007
CEOSourdive (David J.D)
Cellectis SA의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Dr. David Sourdive, Ph.D.
Dr. David Sourdive, Ph.D.
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pierre Bastid
Mr. Pierre Bastid
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Laurent Arthaud
Mr. Laurent Arthaud
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Rainer J. Boehm, M.D.
Dr. Rainer J. Boehm, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stephan Reynier
Mr. Stephan Reynier
Chief Regulatory and Pharmaceutical Compliance Officer
Chief Regulatory and Pharmaceutical Compliance Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Mr. Arthur Stril
Mr. Arthur Stril
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Dr. Steven (Steve) Doares, Ph.D.
Dr. Steven (Steve) Doares, Ph.D.
Senior Vice President - US Manufacturing
Senior Vice President - US Manufacturing
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Dr. David Sourdive, Ph.D.
Dr. David Sourdive, Ph.D.
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pierre Bastid
Mr. Pierre Bastid
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Laurent Arthaud
Mr. Laurent Arthaud
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Rainer J. Boehm, M.D.
Dr. Rainer J. Boehm, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
기업이 아직 관련 데이터를 공개하지 않았습니다.
지역별USD
이름
수익
비율
France
41.51M
0.00%
Other
0.00
0.00%
USA
0.00
0.00%
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Sun, Jan 4
마지막 업데이트: Sun, Jan 4
주주
주주 유형
주주
주주
비율
Long Focus Capital Management LLC
5.70%
B Group, Inc.
4.54%
UBS Asset Management Switzerland AG
1.99%
BlackRock Institutional Trust Company, N.A.
0.48%
Nomura Investment Management Business Trust
0.31%
기타
86.98%
주주
주주
비율
Long Focus Capital Management LLC
5.70%
B Group, Inc.
4.54%
UBS Asset Management Switzerland AG
1.99%
BlackRock Institutional Trust Company, N.A.
0.48%
Nomura Investment Management Business Trust
0.31%
기타
86.98%
주주 유형
주주
비율
Investment Advisor
7.72%
Hedge Fund
6.09%
Investment Advisor/Hedge Fund
0.42%
Research Firm
0.22%
기타
85.55%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
70
10.10M
29.55%
--
2025Q3
77
10.10M
29.65%
-3.45M
2025Q2
79
13.55M
35.05%
-1.95M
2025Q1
82
15.50M
31.47%
-7.25M
2024Q4
86
16.67M
24.79%
+2.93M
2024Q3
104
15.35M
28.39%
+1.55M
2024Q2
103
13.80M
26.34%
-48.27K
2024Q1
112
13.82M
26.53%
-5.23M
2023Q4
124
13.74M
31.43%
+147.34K
2023Q3
142
13.59M
44.11%
-2.54M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Long Focus Capital Management LLC
4.12M
5.7%
-594.03K
-12.59%
Sep 30, 2025
B Group, Inc.
3.28M
4.54%
+25.00K
+0.77%
Sep 30, 2025
UBS Asset Management Switzerland AG
1.44M
1.99%
--
--
Jan 31, 2025
BlackRock Institutional Trust Company, N.A.
337.45K
0.47%
+337.45K
--
Dec 31, 2025
Nomura Investment Management Business Trust
226.88K
0.31%
--
--
Sep 30, 2025
Bellecapital AG
226.07K
0.31%
--
--
Jun 30, 2025
Citadel Advisors LLC
221.96K
0.31%
+221.96K
--
Sep 30, 2025
LPL Financial LLC
85.15K
0.12%
-515.00
-0.60%
Sep 30, 2025
Morgan Stanley & Co. International Plc
83.39K
0.12%
+10.20K
+13.94%
Sep 30, 2025
Millennium Management LLC
57.74K
0.08%
+22.08K
+61.92%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
ActivePassive International Equity ETF
0%
Avantis International Equity ETF
0%
ActivePassive International Equity ETF
비율0%
Avantis International Equity ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
